Oslo, Norway ,December 22, 2021 - An Extraordinary General Meeting ofNykode Therapeutics AS was held onDecember 22, 2021 . All proposed resolutions on the agenda were approved in accordance with the notice for the meeting published onDecember 15, 2021 . Minutes of the meeting are attached hereto. About Nykode Therapeutics Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment cancer and infectious diseases. Nykode Therapeutics' modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses. Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed toGenentech and is in Phase 1b for the treatment of locally advanced and metastatic tumours and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode Therapeutics has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates. The Company has collaborations withRoche ,Genentech andNektar Therapeutics within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and collaborates withAdaptive Biotechnologies for COVID-19 T cell vaccine development. Nykode Therapeutics' shares are traded on Euronext Growth (Oslo ), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is NYKD. Further information about Nykode Therapeutics may be found at http://www.nykode.com Contact forNykode Therapeutics AS : CEOMichael Engsig Nykode Therapeutics AS ir@nykode.comNykode Therapeutics AS Oslo Science Park Gaustadalléen 21 N-0349Oslo, Norway Forward-looking statements for Nykode Therapeutics This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Click here for more information
© Oslo Bors ASA, source